parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enriched in astrocytes (9 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 453	0.79
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 5084

SERPINA3 in dopamine neurons, braak-0.21 (p 0.591) → -0.20 (p 0.597)receipt 5092
SERPINA3 in astrocytes, braak+0.03 (p 0.947) → +0.54 (p 0.130)receipt 5091

receipt 5092: SERPINA3 in dopamine neurons, braak

power: full sample -0.02 (p 0.942, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.00 (p 0.997, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.384, n 18). could be the mix.
skeptic: leave-one-out range -0.14 to +0.10, sign flips 6; without severely affected donors -0.02 (p 0.942, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SERPINA3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5091: SERPINA3 in astrocytes, braak

power: full sample +0.30 (p 0.225, n 18), 95% CI -0.19 to +0.67. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.27 (p 0.273, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.02 (p 0.935, n 18). could be the mix.
skeptic: leave-one-out range +0.22 to +0.46, sign flips 0; without severely affected donors +0.30 (p 0.225, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SERPINA3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts